Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.37 |
| ▸ | PIN1 | Q13526 | 3/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | GALR2 | O43603 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | GSK3B | P49841 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ammonia Solution, Strong SCHEMBL29066096 | 0.98 | TDP1 (0.38) | TDP1SMN1; SMN2HSD17B10ALDH1A1PIN1 | |
| Formamide SCHEMBL29002500 | 0.91 | ALDH1A1 (0.36) | TDP1SMN1; SMN2HSD17B10ALDH1A1PIN1 | |
| SCHEMBL12276575 | 0.84 | PIN1 (0.53) | HSD17B10PIN1 | |
| SCHEMBL8258380 | 0.82 | PIN1 (0.40) | TDP1SMN1; SMN2HSD17B10ALDH1A1PIN1 | |
| SCHEMBL4637128 | 0.80 | PIN1 (0.50) | PIN1 | |
| SCHEMBL10282358 | 0.80 | MAPT (0.51) | TDP1ALDH1A1PIN1MAPTLMNA | |
| SCHEMBL2632674 | 0.80 | ALDH1A1 (0.41) | TDP1SMN1; SMN2HSD17B10ALDH1A1PIN1 | |
| SCHEMBL12639162 | 0.80 | GPR35 (0.42) | TDP1SMN1; SMN2HSD17B10ALDH1A1MAPT | |
| SCHEMBL12639147 | 0.77 | KMT2A (0.43) | TDP1SMN1; SMN2ALDH1A1PIN1MAPT | |
| SCHEMBL12305499 | 0.77 | ALDH1A1 (0.43) | TDP1HSD17B10ALDH1A1PIN1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11713338-B2 | Cyclic peptides multimers targeting α-4-β-7 integrin | ZEALAND PHARMA A/S (DK) | 2023-08-01 | — | — | US | disclosed |
| US-20230219958-A1 | Development of Potential Antidotes for Arsenicals | THE UAB RESEARCH FOUNDATION | 2023-07-13 | — | — | US | disclosed |
| US-20230158035-A1 | SUBSTITUTED AMINOPURINE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | SIGNAL PHARM LLC (US) | 2023-05-25 | — | — | US | disclosed |
| WO-2021213460-A1 | TRICYCLIC KINASE INHIBITOR | 山东轩竹医药科技有限公司 (CN) | 2021-10-28 | — | — | WO | disclosed |
| US-11111273-B2 | Cyclic peptides multimers targeting alpha-4-beta-7 integrin | ZEALAND PHARMA A/S (DK) | 2021-09-07 | — | — | US | disclosed |
| US-20200216501-A1 | CYCLIC PEPTIDES MULTIMERS TARGETING ALPHA-4-BETA-7 INTEGRIN | ZEALAND PHARMA A/S (DK) | 2020-07-09 | — | — | US | disclosed |
| CN-110520127-A | Piperidinyl-substituted and piperazinyl-substituted heteroaromatic carboxamides as modulators of GPR6 | TAKEDA PHARMACEUTICALS CO | 2019-11-29 | — | — | CN | disclosed |
| US-10016436-B2 | Animal and human anti-malarial agents | CELGENE CORPORATION (US) | 2018-07-10 | — | — | US | disclosed |
| CN-108250128-A | Compound as potassium channel modulating agents | 江苏先声药业有限公司 | 2018-07-06 | — | — | CN | disclosed |
| US-10010555-B2 | Animal and human anti-trypanosomonal and anti-leishmania agents | CELGENE CORPORATION (US) | 2018-07-03 | — | — | US | disclosed |
| US-7622463-B2 | Dihydrodiazepines useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-11-24 | — | — | US | disclosed |
| WO-2009093747-A1 | TRICYCLIC COMPOUNDS HAVING CORTICOTROPIN-RELEASING FACTOR ANTAGONISTIC ACTIVITY AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-07-30 | — | — | WO | disclosed |
| US-7550473-B2 | Pyrimidine derivatives useful as inhibitors of PKC-theta | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2009-06-23 | — | — | US | disclosed |
| US-20090156601-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2009-06-18 | — | — | US | disclosed |
| US-7507726-B2 | Peptide deformylase inhibitors | SMITHKLINEBEECHAM CORPORATION (US) | 2009-03-24 | — | — | US | disclosed |
| US-20090042884-A1 | Pharmaceutical Compounds | F.HOFFMANN-LA ROCHE AG (CH) | 2009-02-12 | — | — | US | disclosed |
| US-20080287410-A1 | PYRIMIDINE DERIVATIVES USEFUL AS INHIBITORS OF PKC-THETA | BARBOSA ANTONIO J M | 2008-11-20 | — | — | US | disclosed |
| US-20080167302-A1 | Peptide Deformylase Inhibitors | GLAXOSMITHKLINE LLC | 2008-07-10 | — | — | US | disclosed |
| US-20080167289-A1 | Dihydrodiazepines useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED | 2008-07-10 | — | — | US | disclosed |
| CN-1553909-A | Benzimidazole and pyridylimidazole derivatives as ligands for GABA receptors | — | 2004-12-08 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080287410-A1 | PYRIMIDINE DERIVATIVES USEFUL AS INHIBITORS OF PKC-THETA | PRKCZ, PRKCQ, PRKCH | TDP1 147/4885SMN1; SMN2 3820/4885HSD17B10 3897/4885 |
| US-11111273-B2 | Cyclic peptides multimers targeting alpha-4-beta-7 integrin | ITGB7, ITGB4, ITGA4 | TDP1 4582/4885SMN1; SMN2 3111/4885HSD17B10 4629/4885 |
| US-10010555-B2 | Animal and human anti-trypanosomonal and anti-leishmania agents | TPMT, TYMP, ATIC | TDP1 329/4885SMN1; SMN2 938/4885HSD17B10 4747/4885 |
| US-20090042884-A1 | Pharmaceutical Compounds | PIK3CA, JAK1, PIK3R1 | TDP1 186/4885SMN1; SMN2 1996/4885HSD17B10 2584/4885 |
| US-20230158035-A1 | SUBSTITUTED AMINOPURINE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | TPMT, MGMT, TYMP | TDP1 311/4885SMN1; SMN2 849/4885HSD17B10 4555/4885 |
| US-20090156601-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF CANCER | NR3C1, NR4A3, NR4A1 | TDP1 1346/4885SMN1; SMN2 2087/4885HSD17B10 2932/4885 |
| US-20080167289-A1 | Dihydrodiazepines useful as inhibitors of protein kinases | MAP3K20, MAP3K5, MAP4K2 | TDP1 1088/4885SMN1; SMN2 2058/4885HSD17B10 1762/4885 |
| US-20080167302-A1 | Peptide Deformylase Inhibitors | PDF, PEPD, DPEP1 | TDP1 505/4885SMN1; SMN2 2654/4885HSD17B10 2817/4885 |
| US-10016436-B2 | Animal and human anti-malarial agents | HPRT1, NUDT1, UMPS | TDP1 200/4885SMN1; SMN2 969/4885HSD17B10 3329/4885 |
| US-20230219958-A1 | Development of Potential Antidotes for Arsenicals | RIPK1, RIPK3, RIPK4 | TDP1 1825/4885SMN1; SMN2 4670/4885HSD17B10 4789/4885 |
| US-20200216501-A1 | CYCLIC PEPTIDES MULTIMERS TARGETING ALPHA-4-BETA-7 INTEGRIN | ITGB7, ITGB4, ITGA4 | TDP1 4582/4885SMN1; SMN2 3111/4885HSD17B10 4629/4885 |
| US-11713338-B2 | Cyclic peptides multimers targeting α-4-β-7 integrin | ITGB7, ITGB4, ITGA4 | TDP1 4698/4885SMN1; SMN2 3181/4885HSD17B10 4644/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.